Recombinant Human BCMA (Highly Pure)
Catalog Number: B2010342 (10 ug)
Recombinant Human BCMA is a high quality research product used as highly pure Recombinant Human BCMA expressed in E. coli. This protein acts as a member of tumor necrosis factor receptor superfamily that promotes B-cell survival and plays a role in the regulation of humoral immunity. Custom bulk orders of this product are available upon request.
Recombinant Human BCMA
Catalog number: B2010342
Lot number: Batch Dependent
Expiration Date: Batch dependent
Volume/Weight: 10 ug
pH: 7.4 upon reconstitution
Supplied as: Lyophilized Powder
Applications: highly pure Recombinant Human BCMA expressed in E. coli. This protein acts as a member of tumor necrosis factor receptor superfamily that promotes B-cell survival and plays a role in the regulation of humoral immunity.
Keywords: rHuBCMA; TNFRSF17; CD269; B-cell maturation protein; BCM
Grade: Biotechnology grade. All components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.
1: Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J
Hematol Oncol. 2020 Sep 17;13(1):125.
2: D’Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can
we do better? Leukemia. 2020 Jan;34(1):21-34.
3: Gavriatopoulou M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Anti-BCMA
antibodies in the future management of multiple myeloma. Expert Rev Anticancer
Ther. 2019 Apr;19(4):319-326.
4: Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for
multiple myeloma. Expert Opin Biol Ther. 2019 Nov;19(11):1143-1156.
5: Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in
Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol.
2018 Aug 10;9:1821.
6: Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen
(BCMA) in multiple myeloma: rationale for targeting and current therapeutic
approaches. Leukemia. 2020 Apr;34(4):985-1005.
7: Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M,
Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang
J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N,
Kochenderfer JN. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory
Multiple Myeloma. N Engl J Med. 2019 May 2;380(18):1726-1737.
8: Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, Hudecek M,
Comstock ML, Rajan A, Patel BKR, Voutsinas JM, Wu Q, Liu L, Cowan AJ, Wood BL,
Green DJ, Riddell SR. γ-Secretase inhibition increases efficacy of BCMA-specific
chimeric antigen receptor T cells in multiple myeloma. Blood. 2019 Nov
9: Cho SF, Lin L, Xing L, Li Y, Yu T, Anderson KC, Tai YT. BCMA-Targeting
Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. Cancers
(Basel). 2020 Jun 5;12(6):1473.
10: Feng D, Sun J. Overview of anti-BCMA CAR-T immunotherapy for multiple
myeloma and relapsed/refractory multiple myeloma. Scand J Immunol. 2020
Products Related to Recombinant Human BCMA : Proteins
1- Order online using our website’s automated shopping cart and checkout system (available 24/7).
2- Order by email: firstname.lastname@example.org (we accept electronic PO, available 24/7).
3- Order by Fax: 1-858-437-9884 (available 24/7).
4- Order by phone: 1-858-900-3210 (6 am – 8 pm PST).
5- Order by Text/SMS: 1-858-900-3210 (6 am – 8 pm PST).